NCT06527495 Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma
| NCT ID | NCT06527495 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Assiut University |
| Condition | HCC |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2023-01-01 |
| Primary Completion | 2024-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 150 participants in total. It began in 2023-01-01 with a primary completion date of 2024-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The current study will aim to maximize the therapeutic effect and to minimize the adverse effects of sorafenib in HCC through pharmacogenomic analysis of VEGFA and KDR genetic polymorphisms.
Eligibility Criteria
Inclusion Criteria: * Age of all studied subjects ≥ 18 years old * All patients with hepatocellular carcinoma will be included in group I. * Patients not treated with systemic TKIs Exclusion Criteria: * Patients presented with liver tumors other than HCC. * Patients with Child-Pugh grade C for liver function. * Patients with other malignancies. * Patients with chronic inflammatory disorders. * Patients with severe organ dysfunction such as heart, lung, and kidney. * Patients who cannot tolerate or are allergic to sorafenib. * Patients with severe coagulation dysfunction were uncorrectable. * Age less than 18 years old.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06527495 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying HCC. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06527495 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06527495 currently recruiting?
Yes, NCT06527495 is actively recruiting participants. Contact the research team at Mahmoud.Nazih5698@pharm.aun.edu.eg for enrollment information.
Where is the NCT06527495 trial being conducted?
This trial is being conducted at Shibīn al Kawm, Egypt.
Who is sponsoring the NCT06527495 clinical trial?
NCT06527495 is sponsored by Assiut University. The trial plans to enroll 150 participants.